QuantiFERON-TB Gold Plus

Similar documents
Technical Bulletin No. 172

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive Houston, Texas October 15-17, 2013

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Peggy Leslie-Smith, RN

Approaches to LTBI Diagnosis

TB Intensive Tyler, Texas December 2-4, 2008

Identifying TB co-infection : new approaches?

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

Laboratory Updates on IGRA Testing

Didactic Series. Latent TB Infection in HIV Infection

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

Didactic Series. Latent TB Infection in HIV Infection

No, not these...or these.

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB Prevention Who and How to Screen

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

Investigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

TB in Corrections Phoenix, Arizona

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Screening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.

TB Laboratory for Nurses

Conflict of Interest Disclosures:

ESCMID Online Lecture Library. by author

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

Making the Diagnosis of Tuberculosis

The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?

Interpretation of TST & IGRA results. Objectives

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

L. Masae Kawamura, M.D. Senior Director, Medical and Scientific Affairs, Tuberculosis Clinician, San Francisco TB Clinic DISCLAIMER

Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -

Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?

Tuberculosis Update. Topics to be Addressed

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Diagnosis Latent Tuberculosis. Disclosures. Case

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

The information contained here may be very important to your practice. Please take a moment to review this document.

LIAISON QuantiFERON -TB Gold Plus Solution

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Utility of PPD or IGRA to answer the age old question of "TB or not TB

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

QuantiFERON -TB Gold Plus (QFT -Plus) Package Insert

These recommendations will remain in effect until the national shortage of PPD solution has abated.

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Self-Study Modules on Tuberculosis

Thorax Online First, published on December 8, 2009 as /thx

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment

In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Category Description / Key Findings Publication

Contracts Carla Chee, MHS May 8, 2012

Role of the Laboratory in TB Diagnosis and Management

Update on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town

New NICE guideline updates recommendations for diagnosing latent tuberculosis

A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test

IGRAs for Diagnosis of Tuberculosis: 2010 Update

Mædica - a Journal of Clinical Medicine

Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay

Revised Technical Instructions for Civil Surgeons. October 9, 2018

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS

Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings

LTBI Treatment and Anti TNF alpha

A Clinician s Guide to the TB Laboratory

Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012

Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

Tuberculosis and TNF Inhibitors

Report on WHO Policy Statements

Latent TB Infection (LTBI)

Tuberculosis: Where Are We Now?

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Student Health Requirements Master of Arts, Biomedical Sciences Program

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Richard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction

Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center

International Journal of Innovative Research in Medical Science (IJIRMS)

IGRA Test Reliability. How Test Design and Lab Control Impact Results

How to interpret the new QuantiFERON- TB Gold Plus test (QFT-Plus)

TB Update: March 2012

Transmission and Pathogenesis of Tuberculosis

QuantiFERON -TB Gold Plus (QFT -Plus) ELISA Package Insert

New Standards for an Old Disease:

Diagnosis and Medical Management of LTBI

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Jeffrey R. Starke, M.D. has the following disclosures to make:

Author's response to reviews

More significance of TB- IGRA except for the diagnose of tuberculosis

DEPARTMENT OF THE ARMY OFFICE OF THE SURGEON GENERAL 5109 LEESBURG PIKE FALLS CHURCH, VA

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Transcription:

QuantiFERON-TB Gold Plus A New Interferon-γ Release Assay (IGRA) for the Indirect Detection of Mycobacterium tuberculosis HOT TOPIC / 2018 Presenter: Elitza S. Theel, PhD, D(ABMM) Director of Infectious Diseases Serology Co-Director, Vector-Borne Diseases Service Line Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota MFMER 1

Disclosures None MFMER 3 Utilization Message As you view this presentation, consider the following important points regarding testing: How is the testing going to be used in your practice? When should the tests be used? How will results impact patient management? Begin planning for transition to the new QuantiFERON-Tb Gold Plus assay MFMER 4 2

Evolution of Laboratory Diagnostics for M tuberculosis: Slow Purified protein derivative from attenuated M. tuberculosis (MTb) strain Image courtesy of N.L.Wengenack 1884 1907 1910 2000 2000 2015 Koch s Bacillus Tuberculin Skin Test (TST) Still relying on: TST Culture (4 6 weeks) Direct smear Probe ID Sequencing PCR IGRAs http://phil.cdc.gov/phil/quicksearch.asp Photo credit: Donald Kopanoff MFMER 5 Commercially Available IGRAs for M tuberculosis 3 FDA-cleared IGRAs: T.SPOT-TB (Oxford Immunotec) QuantiFERON-TB Gold In-Tube (QFT-Gold; Qiagen) NEW: QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen) IGRAs are indirect tests for infection with M. tuberculosis (Mtb) Concept: Detect IFN-γ produced by MTb primed T-cells following exposure to MTb antigen Chapter 18 2012 Arroyo Ornelas MA, Arenas Arrocena MC, Estrada HV, Castaño VM, López Marín LM. Published in [short citation] under CC BY 3.0 license. Available from: http://dx.doi.org/10.5772/31421. MFMER 6 3

QuantiFERON-Tb Gold Plus FDA-cleared June 2017 QIAGEN, all rights reserved Developed with the goal to increase sensitivity for both LTBI and active disease Includes peptides to stimulate CD4+ and CD8+ T-cells CD4 T Cell Essential for MTb control Secrete cytokines to regulate/assist immune response IFN γ for macrophage activation cellcartoons.net CD8 T Cell cellcartoons.net Secrete cytokines, including IFN γ Directly kill MTb infected cells Lyse intracellular MTb Mitogen Control QFT-Gold Tb Antigens Nil Control Nil Control QFT-Plus Tb 1 Antigens Tb 2 Antigens Mitogen Control QIAGEN, all rights reserved QIAGEN, all rights reserved Antigens: PHA* ESAT 6, CFP 10, None None Tb7.7 ESAT 6 CFP 10 ESAT 6 CFP 10 Peptide Length/MHC class: Long/Class II Long/Class II Long + short/ Class II + I T Cells Stimulated: CD4+ CD4+ CD4+/CD8+ PHA* *PHA, phythaemagglutinin P MFMER 8 4

QFT-Plus Specimen Collection Transport to Laboratory Draw whole blood into lithium heparin tube Aliquot into QFT Plus tubes and process Mayo Medical Laboratories will only accept incubated and centrifuged QFT Plus Tubes for testing Lithium Heparin tubes will not be accepted For more information on specimen collection, handling and processing of Lithium Heparin tubes please refer to manufacturer instructions or contact Mayo Medical Laboratories for more information MFMER 9 QFT-Plus Processing is Identical to QFT-GIT Processing Mix tubes (Firmly invert 10 times) Incubate at 37C 16 24 hrs Centrifuge to collect plasma APC takes up Tb antigen Tb antigen processed by APC Tb antigen presented to T cell γγ γγ γγ γγ γ γ γ γ T cell produces IFN γ Calculate and Report Results MFMER 10 5

QuantiFERON-TB Gold Plus: Results and Interpretation Nil TB1 Nil TB2 Nil Mitogen Nil QualitativeResult Interpretation 8.0 IU/mL 0.35 and 25% of Nil Any Any Any 0.35 IU/mL and 25% of Nil 0.5 IU/mL <0.35 IU/mL OR 0.35 IU/mL and <25% of Nil <0.5 IU/mL >8.0 IU/mL Any Positive Negative Indeterminate M. tuberculosis infection likely M. tuberculosis infection NOT likely Likelihood of M. tuberculosis infection cannot be determined Cutoff criteria identical to QFT Gold QFT Plus is considered positive if either one or both Tb Ag tubes are positive MFMER 11 Summary The QFT-Plus assay for indirect detection of M. tuberculosis infection received FDA clearance in June 2017 The assay is intended to improve sensitivity for detection of M. tuberculosis over the prior QFT-Gold version Stimulation of both CD4+ and CD8+ T-cells Data suggests non-inferior or similar performance between these two IGRAs Additional studies are ongoing MFMER 12 6

Next Steps Mayo Medical Laboratories will be converting to the QFT-Plus assay on February 13th, 2018 The QFT-Gold test will not be orderable after this date If not already initiated, MML clients are encouraged to begin the conversion process QFT-Plus tubes will be available to order on January 13th, 2018 Consider whether whole blood will be collected into a single lithium-heparin tube vs. directly into the QFT-Plus 4 tubes NOTE: MML will not accept lithium-heparin tubes or unprocessed QFT-Plus tubes For questions and assistance during the conversion process, please contact Mayo Medical Laboratories MFMER 13 References 1. Arroyo-Ornelas MA, Arenas-Arrocena C, Estrada HV, et al. 2012. Immune Diagnosis of Tuberculosis Through Novel Technologies, Understanding Tuberculosis - Global Experiences and Innovative Approaches to the Diagnosis. InTech. Cardona PJ(Ed.). Available from: https://www.intechopen.com/books/understanding-tuberculosis-globalexperiences-and-innovative-approaches-to-the-diagnosis/immunodiagnosis-oftuberculosis-through-novel-technologies 2. Barcellini L, Borroni E, Grown J, et al. 2016. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Euro Resp Soc 48(5):1411-1419 3. Moon HW, Gaur RL, Tien SS, et al. 2017. Evaluation of QuantiFERON-TB Gold-Plus in healthcare workers in a low-incidence setting. J Clin Micro 55(6):1650-1657 4. Telisinghe L, Amofa-Sekyi M, Maluzi K, et al. 2017. The sensitivity of the QuantiFERON-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 21(6):690-696 MFMER 14 7

Questions or requests Email to: MMLHotTopics@mayo.edu For more information Visit MayoMedicalLaboratories.com or call Mayo Laboratory Inquiry at 800-533-1710 HOT TOPIC / 2018 8